210 Participants Needed

ASP1002 for Cancer

Recruiting at 13 trial locations
AP
Overseen ByAstellas Pharma Global Development, Inc.
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Astellas Pharma Global Development, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This trial is testing ASP1002, a new medicine for certain cancers. It focuses on adults with advanced tumors that haven't responded to other treatments. Researchers aim to understand how the body processes ASP1002 and its side effects, to find the best dose for future use.

Do I need to stop my current medications to join the trial?

The trial protocol does not specify if you need to stop taking your current medications. However, if you are on certain cancer treatments, you may need to stop them before starting the trial. It's best to discuss your specific medications with the study team.

How is the drug ASP1002 unique for cancer treatment?

ASP1002 may be unique because it involves S100P, a protein that plays a role in cancer cell growth and spread. S100P is linked to increased cancer cell movement and invasion, making it a potential target for treating cancers where this protein is overexpressed.12345

Research Team

MD

Medical Director

Principal Investigator

Astellas Pharma Global Development, Inc.

Eligibility Criteria

Adults with advanced solid tumors and high claudin 4 levels, who've tried standard treatments or refused them, can join. They must be fairly active (ECOG Status of 0 or 1), expected to live at least 12 weeks, have good organ function, and a measurable tumor. Pregnant women can't join; participants must agree to contraception.

Inclusion Criteria

I have recent tumor tissue samples available.
My cancer is advanced and cannot be removed by surgery.
I will not donate eggs during the trial.
See 13 more

Exclusion Criteria

I have not had major surgery in the last 28 days.
I have untreated brain metastases.
Participant has an active autoimmune disease.
See 20 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment Part 1: Dose Escalation

Participants receive sequentially escalating doses of ASP1002 to determine suitable doses for Part 2

Up to 24 months
Weekly or bi-weekly visits for infusions and health checks

Treatment Part 2: Dose Expansion

Participants receive doses of ASP1002 determined from Part 1

Up to 24 months
Weekly or bi-weekly visits for infusions and health checks

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 12 months
Visits at 1 month, 3 months, and up to 1 year after last dose

Treatment Details

Interventions

  • ASP1002
Trial OverviewASP1002 is being tested in two parts: first to find safe doses by giving it through an IV in increasing amounts to small groups. Then the best doses are used on different groups for up to two years or until side effects become too severe.
Participant Groups
4Treatment groups
Experimental Treatment
Group I: Experimental: ASP1002 Dose Expansion (Part 2) colorectal cancer (CRC)Experimental Treatment1 Intervention
Participants will receive ASP1002 with dose/regimen selected from dose escalation (Part 1).
Group II: Experimental: AS1002 Dose Expansion (Part 2) urothelial carcinoma (UC)Experimental Treatment1 Intervention
Participants will receive ASP1002 with dose/regimen selected from dose escalation (Part 1).
Group III: ASP1002 Dose Expansion (Part 2) non-small cell lung cancer (NSCLC)Experimental Treatment1 Intervention
Participants will receive ASP1002 with dose/regimen selected from dose escalation (Part 1).
Group IV: ASP1002 Dose Escalation (Part 1)Experimental Treatment1 Intervention
Participants will be assigned to sequentially escalating doses of ASP1002. Each dose level will open sequentially based upon sponsor review of emerging data.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Astellas Pharma Global Development, Inc.

Lead Sponsor

Trials
204
Recruited
123,000+

Tadaaki Taniguchi

Astellas Pharma Global Development, Inc.

Chief Medical Officer

M.D., Ph.D.

Naoki Okamura profile image

Naoki Okamura

Astellas Pharma Global Development, Inc.

Chief Executive Officer

Not available

Findings from Research

In a study of 121 patients with resectable gastric cancer, those with positive S100P expression had a significantly higher 5-year cumulative survival rate (20.3%) compared to those with negative expression (3.5%), suggesting S100P may serve as a novel independent prognostic factor.
The overexpression of S100P in gastric cancer cells increased their sensitivity to the chemotherapy drug oxaliplatin, as indicated by a lower half-inhibitory concentration (IC50) in S100P-overexpressing cells, which could enhance treatment outcomes for patients.
[Impact of S100P expression on clinical outcomes of gastric cancer patients with adjuvant chemotherapy of oxaliplatin and its mechanisms].Zhao, XM., Bai, ZG., Ma, XM., et al.[2018]
S100P is significantly overexpressed in endometrial squamous cell carcinoma and adenosquamous carcinoma, suggesting its potential as a specific biomarker for these cancer subtypes.
The study indicates that S100P promotes tumor growth by enhancing cell proliferation, invasion, and migration while inhibiting apoptosis, likely through activation of the PI3K-AKT and MAPK pathways, making it a potential target for therapeutic intervention.
S100P is Overexpressed in Squamous Cell and Adenosquamous Carcinoma Subtypes of Endometrial Cancer and Promotes Cancer Cell Proliferation and Invasion.Jiang, H., Hu, H., Lin, F., et al.[2017]
S100P is a key protein that promotes migration, invasion, and metastasis in lung cancer cells, with its effects linked to increased interaction with integrin α7 and activation of signaling pathways like FAK and AKT.
Knocking down S100P not only reduces cancer cell movement and invasion but also prevents the spread of highly metastatic lung cancer in animal models, suggesting that targeting S100P could be a promising strategy for lung cancer treatment.
S100P interacts with integrin α7 and increases cancer cell migration and invasion in lung cancer.Hsu, YL., Hung, JY., Liang, YY., et al.[2018]

References

[Impact of S100P expression on clinical outcomes of gastric cancer patients with adjuvant chemotherapy of oxaliplatin and its mechanisms]. [2018]
S100P is Overexpressed in Squamous Cell and Adenosquamous Carcinoma Subtypes of Endometrial Cancer and Promotes Cancer Cell Proliferation and Invasion. [2017]
S100P interacts with integrin α7 and increases cancer cell migration and invasion in lung cancer. [2018]
Calcium-binding protein S100P and cancer: mechanisms and clinical relevance. [2021]
[Clinical significance of S100A8 and S100A9 expression in gastric cancer]. [2014]